Figure 1. Overall Survival (OS) with a Second Allogeneic Hematopoietic Cell Transplant (Allo-HCT2) vs Donor Lymphocyte Infusion (DLI) in All Patients.
Two-year OS for allo-HCT2, 26% (95% CI, 19%-33%) and DLI, 25% (95% CI, 20%-30%) (P = .86).
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.